CPSF4

Across TCGA pan-cancer cohorts, CPSF4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CPSF4 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CPSF4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CPSF4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where CPSF4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.350	0.721	<.001	26	view →
LSCC	OS	Tertile	II,III,IV	0.927	0.573	.013	13	view →
UCEC	DFS	Median	All	1.000	0.936	.023	10	view →
CCRCC	OS	Median	All	0.890	1.000	.004	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	DFS	Quartile	III,IV	0.860	1.000	.016	5	view →
LUAD	OS	Median	II,III,IV	0.442	0.899	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CPSF4–PDAC (OS)

Open the PDAC breakdown →